LUNG
HEALTHCAREPulmonx Corp
$1.29+0.02 (+1.57%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving LUNG Today?
No stock-specific AI insight has been generated for LUNG yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.13$3.88
$1.29
Fundamentals
Market Cap$54M
P/E Ratio—
EPS$-1.30
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin-0.6%
Debt / Equity—
Trading
Volume610K
Avg Volume (10D)—
Shares Outstanding42.2M
LUNG News
20 articles- Pulmonx (LUNG) Q1 2026 Earnings TranscriptMotley Fool·Apr 30, 2026
- Pulmonx Corporation Q1 2026 Earnings Call SummaryMoby·Apr 30, 2026
- Pulmonx Corp (LUNG) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...Yahoo Finance·Apr 30, 2026
- Pulmonx Q1 Earnings Call HighlightsMarketbeat·Apr 29, 2026
- Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·Apr 29, 2026
- Pulmonx Reports First Quarter 2026 Financial ResultsYahoo Finance·Apr 29, 2026
- Pulmonx to Present at the Bank of America Securities 2026 Health Care ConferenceYahoo Finance·Apr 28, 2026
- How The Pulmonx (LUNG) Investment Narrative Is Resetting Around A Lower Target And Execution RiskYahoo Finance·Apr 19, 2026
- Hims & Hers Health (HIMS) Soars 11.1%: Is Further Upside Left in the Stock?Yahoo Finance·Apr 17, 2026
- Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026Yahoo Finance·Apr 15, 2026
- How The Pulmonx (LUNG) Investment Story Is Shifting After Q4 And New GuidanceYahoo Finance·Apr 5, 2026
- TruBridge (TBRG) Beats Q4 Earnings EstimatesYahoo Finance·Mar 31, 2026
- How The Pulmonx (LUNG) Narrative Is Resetting Around Execution Risks And Fair Value AssumptionsYahoo Finance·Mar 21, 2026
- Pulmonx Corporation Q4 2025 Earnings Call SummaryMoby·Mar 5, 2026
- Pulmonx Corp (LUNG) Q4 2025 Earnings Call Highlights: Strategic Restructuring and Sales Force ...Yahoo Finance·Mar 5, 2026
- Pulmonx Q4 Earnings Call HighlightsMarketbeat·Mar 5, 2026
- Pulmonx (LUNG) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 4, 2026
- Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 4, 2026
- Pulmonx Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 4, 2026
- Pulmonx Announces Closing of up to $60 Million Credit FacilityYahoo Finance·Mar 4, 2026
All 20 articles loaded
Price Data
Open$1.27
Previous Close$1.27
Day High$1.31
Day Low$1.26
52 Week High$3.88
52 Week Low$1.13
52-Week Range
$1.13$3.88
$1.29
Fundamentals
Market Cap$54M
P/E Ratio—
EPS$-1.30
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin-0.6%
Debt / Equity—
Trading
Volume610K
Avg Volume (10D)—
Shares Outstanding42.2M
About Pulmonx Corp
Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. The company is headquartered in Redwood City, California.
HEALTHCAREMEDICAL DEVICES
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICMEDICAL DEVICES
CIK—
Composite FIGI—
Share Class FIGI—